Core Insights - Supernus Pharmaceuticals, Inc. is a mid-cap biopharmaceutical company focused on central nervous system diseases, aiming for growth through both commercial and pipeline products, particularly in epilepsy, ADHD, and Parkinson's disease [1] - The company reported a full-year 2025 revenue of $719.0 million, reflecting a 9% year-over-year increase, with growth products contributing $521.8 million, a 40% increase driven by Qelbree and GOCOVRI [7] - Despite revenue growth, Supernus experienced a net loss of $38.6 million for the year due to higher operating costs associated with acquisitions and commercialization efforts [7] Company Transactions - Padmanabh P. Bhatt, Sr. VP of IP and CSO at Supernus, sold 107,250 shares of Common Stock from March 16 to March 18, 2026, for approximately $5.4 million [5] - The sale was executed under a prearranged Rule 10b5-1 plan, and the elevated volume reflects a reduction in remaining holdings rather than a change in selling behavior [2][6] - Bhatt's direct Common Stock ownership decreased to 17,044 shares, but he retains 39,500 Employee Stock Options, which could provide future equity exposure [3] Business Strategy and Outlook - Supernus is transitioning towards a broader CNS portfolio with multiple growth drivers, emphasizing the importance of margin stability for long-term investors [8] - The company is leveraging established distribution channels to maintain a competitive presence in the specialty pharmaceutical sector [1]

Supernus Pharmaceuticals FY Conference Summary Company Overview - **Company**: Supernus Pharmaceuticals (NasdaqGM:SUPN) - **Date of Conference**: March 02, 2026 - **Key Speakers**: Jack Khattar (CEO), Timothy C. Dec (CFO) Key Points Industry and Company Position - Supernus is positioned differently today with a diverse portfolio of products, moving beyond reliance on a single product [2] - The company has four growth products and is experiencing accelerated growth with an exciting pipeline [2][3] Product Performance - **ONAPGO**: Recently reinitiated patient treatment after resolving supply constraints. The product has strong demand, evidenced by 500 patient forms submitted during supply issues [4][5][6] - **ZURZUVAE**: Launched with a focus on educating women about postpartum depression, aiming to increase awareness and usage [51][52] - **Qelbree**: Continues to perform well, with a stable mix of adult and pediatric prescriptions. The product is underutilized in the non-stimulant segment, presenting significant growth potential [42][43][44] Financial Guidance - ONAPGO revenue guidance is set between $45 million and $70 million, influenced by supply, demand, and fulfillment rates [24][26] - Peak sales for ONAPGO may exceed initial estimates of $200 million to $300 million due to overwhelming demand [38][40] Patient Demand and Market Dynamics - Demand for ONAPGO is strong, with patients willing to wait through supply disruptions rather than switch to competitors [10][12] - The company anticipates a conversion rate of 15%-25% from patient forms to actual patients, which is typical in the industry [22] Pipeline and Future Developments - The company is optimistic about its pipeline, with promising assets in Phase 2b studies expected to yield data in 2027 [59] - Supernus is actively pursuing business development opportunities, focusing on revenue-generating assets and later-stage products [58] Manufacturing and Supply Chain - A second supplier is expected to come online in 2027, which will help mitigate supply issues [29][32] - The company is working to streamline the patient initiation process to reduce friction points in fulfillment [23] Market Education and Awareness - Significant investment in educating healthcare providers and patients about ZURZUVAE and its benefits over traditional SSRIs [51][52][55] - The company aims to establish ZURZUVAE as the standard of care for postpartum depression [55] Conclusion - Supernus Pharmaceuticals is navigating a transformative phase with a robust product pipeline and strategic focus on market education and patient demand. The company is well-positioned for growth in the coming years, particularly with ONAPGO and ZURZUVAE.

Biogen FY Conference Summary Company Overview - **Company**: Biogen (NasdaqGS:BIIB) - **Event**: TD Cowen's 46th Annual Healthcare Conference - **Date**: March 02, 2026 Key Points Industry and Company Focus - Biogen is in a phase of rebuilding and expanding its portfolio, with a focus on late-stage pipeline development, currently having **10 Phase 3 programs** underway, with the first results expected this year [1][2] - The company has reduced R&D spending by **25%** over the past three years while increasing productivity [2] Revenue and Growth Outlook - Biogen anticipates a **mid-single digit percentage decline** in revenue for 2026, but is optimistic about returning to growth due to new product launches and a strong late-stage pipeline [4] - The company has launched four growth products in the last three years, including LEQEMBI and QALSODY, which have outpaced declines in the MS portfolio [4][5] Product Pipeline and Launches - Upcoming product launches include: - **Felzartamab** for lupus - **Salanersen**, a successor to SPINRAZA - **Zorevunersen** for Dravet syndrome - Positive results from these launches could significantly enhance growth [5] Business Development Strategy - Biogen is cautious with M&A, indicating that replacing **$1 billion** of after-tax profit would require **$15 billion-$20 billion**, which is beyond its current capacity [7] - The focus is on early-stage assets with promising Phase 3 results to complement the existing pipeline [8] LEQEMBI Launch Insights - The launch of LEQEMBI is described as complex, requiring significant adjustments in physician practices, including managing infusion beds and patient monitoring [10] - Reimbursement for LEQEMBI has not been a major issue, which has helped build physician confidence [10][11] - The introduction of blood-based diagnostics has improved patient triage and increased the eligible patient pool for treatment [12][13] Future Trials and Research - The **AHEAD 3-45 trial** is expected to provide critical insights into early Alzheimer's treatment, potentially preventing the onset of symptoms by targeting amyloid buildup [20][22] - The trial aims to determine the incidence of ARIA (Amyloid-related imaging abnormalities) and the long-term effects of early treatment [21][24] Other Product Developments - **SPINRAZA** is set for a milestone with a PDUFA for high-dose approval, which could shift competitive dynamics in the SMA field [28] - **Salanersen** is being developed to address intrathecal fatigue, with promising early results in children previously treated with gene therapy [32] Multiple Sclerosis Portfolio - Biogen expects a **mid-teens decline** in its MS franchise, primarily due to the aging product portfolio and competition from biosimilars [39] - The company is focusing on maintaining market share through patient support services and effective management of existing therapies [43][44] Conclusion - Biogen is strategically positioned to navigate challenges in the biotech landscape with a robust pipeline and a focus on innovative therapies, while also managing the complexities of product launches and market dynamics. The company is optimistic about future growth driven by new product introductions and ongoing clinical trials.

Core Insights - Supernus Pharmaceuticals achieved record revenues of $719 million in 2025, driven by a 40% revenue increase from four key products: Qelbree, GOCOVRI, ZURZUVAE, and ONAPGO, which now account for 76% of total revenues [4] - The company successfully integrated the acquisition of Sage Therapeutics, adding ZURZUVAE to its portfolio and establishing a presence in the women's health and postpartum depression markets [4] - Projected total revenues for 2026 are estimated to be between $840 million and $870 million, with ONAPGO expected to contribute $45 million to $70 million as supply stabilizes [4] Strategic Performance and Operational Context - The company managed ONAPGO supply constraints by prioritizing existing patient maintenance and preparing to resume new patient initiations in early 2026 [4] - Qelbree's fourth-quarter net sales lagged behind prescription growth due to an unexpected $4 million PBM bill for the full year of 2025 [4] - The company maintains a disciplined R&D approach, retaining high-potential Sage assets for internal development while seeking external partnerships for early-stage pipeline candidates [4] 2026 Outlook and Strategic Priorities - The strategic focus for 2026 includes clearing the ONAPGO patient backlog and transitioning to a second manufacturing supplier by 2027 to ensure long-term capacity [4] - The M&A strategy is focused on revenue-generating assets or late-stage pipeline candidates that could launch between 2027 and 2031 [4] - Clinical timelines for SPN-820 (depression) and SPN-817 (epilepsy) target top-line data readouts in 2027, with SPN-820 expected to recruit faster due to the indication type [4] Financial Performance - The company recorded $73 million in acquisition-related costs and $50 million in incremental operating costs associated with the Sage Therapeutics transaction in 2025 [4] - A GAAP operating loss of $62.3 million was reported for 2025, primarily due to one-time acquisition expenses and higher intangible asset amortization for new products [4] Market Opportunities - A 700-patient queue for ONAPGO awaiting benefit verification represents a significant near-term revenue conversion opportunity as supply resumes [6] - High demand for ONAPGO exists, but the conversion of 1,800 enrollment forms to active patients is subject to typical specialty pharmacy attrition and reimbursement hurdles [6]

Core Insights - Supernus Pharmaceuticals reported $211.57 million in revenue for Q4 2025, marking a 21.5% year-over-year increase and exceeding the Zacks Consensus Estimate by 7.57% [1] - The company's EPS for the same quarter was $0.92, a significant increase from $0.75 a year ago, resulting in an EPS surprise of 228.57% compared to the consensus estimate of $0.28 [1] Revenue Performance - Trokendi XR generated $8.4 million in net product sales, below the average estimate of $5.81 million, reflecting a year-over-year decline of 43.2% [4] - Oxtellar XR reported $6.8 million in net product sales, surpassing the average estimate of $5.75 million, but showing a year-over-year decrease of 48.5% [4] - APOKYN achieved $9.6 million in net product sales, slightly below the average estimate of $9.93 million, with a year-over-year decline of 52.2% [4] - Qelbree's net product sales were $81 million, below the average estimate of $87.72 million, but showing an 8.9% year-over-year increase [4] - Collaboration revenue from ZURZUVAE was $32.8 million, exceeding the average estimate of $28.05 million [4] - Total net product sales amounted to $158.1 million, below the average estimate of $193.42 million, representing a year-over-year decline of 5% [4] - Royalty, licensing, and other revenues reached $20.7 million, significantly above the average estimate of $3.25 million, with a year-over-year increase of 166.6% [4] - ONAPGO net product sales were $8.9 million, exceeding the average estimate of $6.1 million [4] - GOCOVRI generated $38.6 million in net product sales, slightly below the average estimate of $42.64 million, with a year-over-year increase of 4.6% [4] Stock Performance - Supernus shares have returned +3.1% over the past month, contrasting with a -1% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 5 (Strong Sell), indicating potential underperformance relative to the broader market in the near term [3]

Core Insights - Supernus Pharmaceuticals reported significant progress in 2025, achieving record total revenues and successfully launching ONAPGO for Parkinson's disease [2][4] - The company is focused on advancing its key growth products and resuming new patient initiation for ONAPGO in 2026 [2] Financial Performance - Total revenues for Q4 2025 reached $211.6 million, a 21% increase year-over-year, while full-year revenues were $719.0 million, up 9% from 2024 [4][8] - Combined revenues from the company's four growth products increased to $161.3 million in Q4 2025, representing a 45% year-over-year growth, and $521.8 million for the full year, a 40% increase [4][8] - Cash, cash equivalents, and current marketable securities totaled $308.7 million as of December 31, 2025 [4] Product Highlights - ONAPGO net product sales were $8.9 million in Q4 2025, following its U.S. launch in April 2025, with over 1,800 enrollment forms submitted by more than 540 prescribers [5] - Collaboration revenue from ZURZUVAE was $32.8 million in Q4 2025, with U.S. sales increasing approximately 187% compared to Q4 2024 [5] - Net sales of Qelbree increased 9% to $81.0 million in Q4 2025, while GOCOVRI sales rose 5% to $38.6 million [5] Research and Development - The company is conducting a Phase 2b study for SPN-817, a novel AChE inhibitor for epilepsy, and has initiated a Phase 2b trial for SPN-820, a treatment for major depressive disorder [6] - SPN-443, a novel stimulant for ADHD, is expected to enter Phase 1 trials in the second half of 2026 [6] Financial Guidance - For full year 2026, Supernus expects total revenues between $840 million and $870 million, with operating earnings projected at $0 million to $30 million [10] - ONAPGO net sales are anticipated to be between $45 million and $70 million, while Trokendi XR and Oxtellar XR net sales are expected to be $40 million to $50 million [10]

Core Insights - Biogen Inc. reported better-than-expected fourth-quarter earnings with adjusted EPS of $1.99, surpassing the consensus of $1.59, and revenues of $2.28 billion, exceeding the consensus of $2.20 billion, although down 7% year-over-year on both reported and constant currency basis [1][3] Financial Performance - The company achieved nearly $1 billion in revenue from its products LEQEMBI, SKYCLARYS, ZURZUVAE, and QALSODY, reflecting strong execution and financial discipline [2] - For fiscal 2026, Biogen expects earnings between $15.25 and $16.25 per share, above the consensus estimate of $14.92, but anticipates a mid-single-digit revenue decline compared to 2025 due to expected declines in Multiple Sclerosis product revenue, partially offset by growth in other areas [3] Market Reaction - Following the earnings announcement, Biogen shares fell 0.9% to $199.40 in pre-market trading [3] - Analysts have adjusted their price targets for Biogen, with Piper Sandler maintaining a Neutral rating and raising the target from $157 to $177, HC Wainwright & Co. maintaining a Buy rating and increasing the target from $194 to $228, and Wedbush maintaining a Neutral rating with a target increase from $178 to $187 [4]

Core Insights - Biogen Inc. reported better-than-expected fourth-quarter earnings with adjusted EPS of $1.99, surpassing the consensus of $1.59, and revenues of $2.28 billion, exceeding the consensus of $2.20 billion, although down 7% year-over-year [1][3] Financial Performance - The company generated nearly $1 billion in revenue from its drugs LEQEMBI, SKYCLARYS, ZURZUVAE, and QALSODY, reflecting strong execution and financial discipline [2] - For fiscal 2026, Biogen expects earnings between $15.25 and $16.25 per share, above the consensus estimate of $14.92, but anticipates a mid-single-digit revenue decline compared to 2025 due to expected declines in Multiple Sclerosis product revenue [3] Stock Performance and Analyst Ratings - Following the earnings announcement, Biogen shares fell 0.9% to $199.40 in pre-market trading [3] - Analysts have adjusted their price targets for Biogen, with Piper Sandler maintaining a Neutral rating and raising the target from $157 to $177, HC Wainwright & Co. maintaining a Buy rating and increasing the target from $194 to $228, and Wedbush maintaining a Neutral rating with a target increase from $178 to $187 [4]

Core Viewpoint - Biogen Inc. reported stronger-than-expected fourth-quarter 2025 results, leading to a more than 3% increase in shares, and provided an optimistic profit outlook for 2026 [1] Financial Performance - Adjusted earnings per share for Q4 2025 were $1.99, exceeding the analyst consensus of $1.61 [1] - Revenue for the quarter was $2.28 billion, surpassing expectations of $2.21 billion, although it represented a 7% decline year over year [1] Growth Products - Growth products showed positive momentum, with revenue increasing by 6% year over year in the quarter [2] - Global in-market sales of LEQEMBI reached approximately $134 million, marking a 54% year-over-year increase [2] - ZURZUVAE generated about $66 million in revenue, indicating strong demand growth [2] - SKYCLARYS expanded its global patient base by roughly 30% in 2025 [2] 2026 Outlook - For fiscal 2026, Biogen forecasts adjusted earnings per share in the range of $15.25 to $16.25, above the analyst consensus of $14.92 [3] - The company anticipates total revenue to decline by a mid-single-digit percentage compared to 2025, with expected declines in multiple sclerosis products, excluding VUMERITY, partially offset by growth in newer therapies [3]

February 6, 2026 Q4 AND FULL YEAR 2025 FINANCIAL RESULTS AND BUSINESS UPDATE FORWARD-LOOKING STATEMENTS This presentation and discussions during this conference call contain forward-looking statements, relating to: our strategy and plans; potential of, and expectations for, our commercial business and pipeline programs; capital allocation and investment strategy; clinical development programs, clinical trials, and data readouts and presentations; regulatory discussions, submissions, filings, and approvals; ...